Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics

Journal of Controlled Release

Volumn 203, Issue , 2015, Pages 1-15

  Lorenzer, Cornelia ^a   Dirin, Mehrdad ^a   Winkler, Anna Maria ^a   Baumann, Volker ^a   Winkler, Johannes ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bioconjugates; Delivery systems; Liposomes; RNA interference; siRNA; Targeting

Indexed keywords

BIOMOLECULES; BLOOD; CELL MEMBRANES; DISEASE CONTROL; GENE THERAPY; LIPOSOMES; OLIGONUCLEOTIDES; PARTICLE SIZE; TISSUE; TUMORS;

BIOCONJUGATES; DELIVERY SYSTEMS; RNA INTERFERENCE; SIRNA; TARGETING;

LIGANDS;

LIGAND; NANOPARTICLE; OLIGONUCLEOTIDE; SMALL INTERFERING RNA; LIPOSOME;

BLOOD BRAIN BARRIER; CELL MIGRATION; CONJUGATION; DRUG DELIVERY SYSTEM; ENDOTHELIUM; HUMAN; LEUKOCYTE; LIVER; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; GENE TRANSFER; METABOLISM; NEOPLASMS; PROCEDURES; RNAI THERAPEUTICS;

ANIMALS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; ENDOTHELIUM; GENE TRANSFER TECHNIQUES; HUMANS; LEUKOCYTES; LIPOSOMES; LIVER; MODELS, MOLECULAR; NANOPARTICLES; NEOPLASMS; RNA, SMALL INTERFERING; RNAI THERAPEUTICS;

EID: 84922724331     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.02.003     Document Type: Review

References (186)

1. J.C. Burnett, and J.J. Rossi RNA-based therapeutics: current progress and future prospects Chem. Biol. 19 2012 60 71
2. M.R. Lares, J.J. Rossi, and D.L. Ouellet RNAi and small interfering RNAs in human disease therapeutic applications Trends Biotechnol. 28 2010 570 579
3. T. Coelho, D. Adams, A. Silva, P. Lozeron, P.N. Hawkins, T. Mant, J. Perez, J. Chiesa, S. Warrington, E. Tranter, M. Munisamy, R. Falzone, J. Harrop, J. Cehelsky, B.R. Bettencourt, M. Geissler, J.S. Butler, A. Sehgal, R.E. Meyers, Q. Chen, T. Borland, R.M. Hutabarat, V.A. Clausen, R. Alvarez, K. Fitzgerald, C. Gamba-Vitalo, S.V. Nochur, A.K. Vaishnaw, D.W.Y. Sah, J.A. Gollob, and O.B. Suhr Safety and efficacy of RNAi therapy for transthyretin amyloidosis N. Engl. J. Med. 369 2013 819 829
4. C.I. Wooddell, D.B. Rozema, M. Hossbach, M. John, H.L. Hamilton, Q. Chu, J.O. Hegge, J.J. Klein, D.H. Wakefield, C.E. Oropeza, J. Deckert, I. Roehl, K. Jahn-Hofmann, P. Hadwiger, H.-P. Vornlocher, A. McLachlan, and D.L. Lewis Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection Mol. Ther. 21 2013 973 985
5. B. Sjouke, D.M.W. Balak, U. Beuers, V. Ratziu, and E.S.G. Stroes Is mipomersen ready for clinical implementation? A transatlantic dilemma Curr. Opin. Lipidol. 24 2013 301 306
6. T. Yamamoto, M. Nakatani, K. Narukawa, and S. Obika Antisense drug discovery and development Future Med. Chem. 3 2011 339 365
7. M. Dirin, and J. Winkler Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides Expert. Opin. Biol. Ther. 13 2013 875 888
8. A.D. Keefe, S. Pai, and A. Ellington Aptamers as therapeutics Nat. Rev. Drug Discov. 9 2010 537 550
9. S. Cirak, V. Arechavala-Gomeza, M. Guglieri, L. Feng, S. Torelli, K. Anthony, S. Abbs, M.E. Garralda, J. Bourke, D.J. Wells, G. Dickson, M.J.A. Wood, S.D. Wilton, V. Straub, R. Kole, S.B. Shrewsbury, C. Sewry, J.E. Morgan, K. Bushby, and F. Muntoni Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study Lancet 378 2011 595 605
10. N.M. Goemans, M. Tulinius, J.T. van den Akker, B.E. Burm, P.F. Ekhart, N. Heuvelmans, T. Holling, A.A. Janson, G.J. Platenburg, J.A. Sipkens, J.M. Sitsen, A. Aartsma-Rus, G.J. van Ommen, G. Buyse, N. Darin, J.J. Verschuuren, G.V. Campion, S.J. de Kimpe, and J.C. van Deutekom Systemic administration of PRO051 in Duchenne's muscular dystrophy N. Engl. J. Med. 364 2011 1513 1522
11. M. Lindow, and S. Kauppinen Discovering the first microRNA-targeted drug J. Cell Biol. 199 2012 407 412
12. M. Jurk, and J. Vollmer Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation BioDrugs 21 2007 387 401
13. R. Bhindi, R.G. Fahmy, H.C. Lowe, C.N. Chesterman, C.R. Dass, M.J. Cairns, E.G. Saravolac, L.Q. Sun, and L.M. Khachigian Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies Am. J. Pathol. 171 2007 1079 1088
14. R.M. Orr Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision Curr. Opin. Mol. Ther. 3 2001 288 294
15. T.R. Friberg, M. Tolentino, P. Weber, S. Patel, S. Campbell, and M. Goldbaum Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study Br. J. Ophthalmol. 94 2010 1611 1617
16. D.N. Ricotta, and W. Frishman Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia Cardiol. Rev. 20 2012 90 95
17. F. Eckstein Phosphorothioates, essential components of therapeutic oligonucleotides Nucleic Acid Ther. 24 2014 374 387
18. M. Stessl, M. Marchetti-Deschmann, J. Winkler, B. Lachmann, G. Allmaier, and C.R. Noe A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells J. Proteomics 72 2009 1019 1030
19. J. Winkler, M. Stessl, J. Amartey, and C.R. Noe Off-target effects related to the phosphorothioate modification of nucleic acids ChemMedChem 5 2010 1344 1352
20. M.P. McGowan, J.-C. Tardif, R. Ceska, L.J. Burgess, H. Soran, I. Gouni-Berthold, G. Wagener, and S. Chasan-Taber Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy PLoS ONE 7 2012 e49006
21. C. Gelsinger, E. Steinhagen-Thiessen, and U. Kassner Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia Drugs 72 2012 1445 1455
22. M.E. Visser, G. Wagener, B.F. Baker, R.S. Geary, J.M. Donovan, U.H. Beuers, A.J. Nederveen, J. Verheij, M.D. Trip, D.C. Basart, J.J. Kastelein, and E.S. Stroes Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial Eur. Heart J. 33 2012 1142 1149
23. E.M. Straarup, N. Fisker, M. Hedtjärn, M.W. Lindholm, C. Rosenbohm, V. Aarup, H.F. Hansen, H. Orum, J.B.R. Hansen, and T. Koch Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates Nucleic Acids Res. 38 2010 7100 7111
24. S.P. Henry, M. Johnson, T.A. Zanardi, R. Fey, D. Auyeung, P.B. Lappin, and A.A. Levin Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey Toxicology 301 2012 13 20
25. E.S. Hildebrandt-Eriksen, V. Aarup, R. Persson, H.F. Hansen, M.E. Munk, and H. Orum A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys Nucleic Acid Ther. 22 2012 152 161
26. M.A. Scully, S. Pandya, and R.T. Moxley Review of Phase II and Phase III clinical trials for Duchenne muscular dystrophy Expert Opin. Orphan Drugs 1 2013 33 46
27. A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811
28. C.F. Bennett, and E.E. Swayze RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform Annu. Rev. Pharmacol. Toxicol. 50 2010 259 293
29. A.O. Garba, and S.A. Mousa Bevasiranib for the treatment of wet, age-related macular degeneration Ophthalmol. Eye Dis. 2 2010 75 83
30. K.A. Whitehead, R. Langer, and D.G. Anderson Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discov. 8 2009 129 138
31. R. Juliano, J. Bauman, H. Kang, and X. Ming Biological barriers to therapy with antisense and siRNA oligonucleotides Mol. Pharm. 6 2009 686 695
32. B.A. Kraynack, and B.F. Baker Small interfering RNAs containing full 2′-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity RNA 12 2006 163 176
33. M. Manoharan, A. Akinc, R.K. Pandey, J. Qin, P. Hadwiger, M. John, K. Mills, K. Charisse, M.A. Maier, L. Nechev, E.M. Greene, P.S. Pallan, E. Rozners, K.G. Rajeev, and M. Egli Unique gene-silencing and structural properties of 2′-fluoro-modified siRNAs Angew. Chem. Int. Ed. Engl. 50 2011 2284 2288
34. P.S. Pallan, E.M. Greene, P.A. Jicman, R.K. Pandey, M. Manoharan, E. Rozners, and M. Egli Unexpected origins of the enhanced pairing affinity of 2′-fluoro-modified RNA Nucleic Acids Res. 39 2011 3482 3495
35. K. Fluiter, O.R. Mook, and F. Baas The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence Methods Mol. Biol. 487 2009 189 203
36. S.A. Moschos, M. Frick, B. Taylor, P. Turnpenny, H. Graves, K.G. Spink, K. Brady, D. Lamb, D. Collins, T.D. Rockel, M. Weber, O. Lazari, L. Perez-Tosar, S.A. Fancy, C. Lapthorn, M.X. Green, S. Evans, M. Selby, G. Jones, L. Jones, S. Kearney, H. Mechiche, D. Gikunju, R. Subramanian, E. Uhlmann, M. Jurk, J. Vollmer, G. Ciaramella, and M. Yeadon Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense Mol. Ther. 19 2011 2163 2168
37. J. Winkler Oligonucleotide conjugates for therapeutic applications Ther. Deliv. 4 2013 791 809
38. B. Ozpolat, A.K. Sood, and G. Lopez-Berestein Liposomal siRNA nanocarriers for cancer therapy Adv. Drug Deliv. Rev. 66 2014 110 116
39. S.C. Semple, A. Akinc, J. Chen, A.P. Sandhu, B.L. Mui, C.K. Cho, D.W.Y. Sah, D. Stebbing, E.J. Crosley, E. Yaworski, I.M. Hafez, J.R. Dorkin, J. Qin, K. Lam, K.G. Rajeev, K.F. Wong, L.B. Jeffs, L. Nechev, M.L. Eisenhardt, M. Jayaraman, M. Kazem, M.A. Maier, M. Srinivasulu, M.J. Weinstein, Q. Chen, R. Alvarez, S.A. Barros, S. De, S.K. Klimuk, T. Borland, V. Kosovrasti, W.L. Cantley, Y.K. Tam, M. Manoharan, M.A. Ciufolini, M.A. Tracy, A. de Fougerolles, I. MacLachlan, P.R. Cullis, T.D. Madden, and M.J. Hope Rational design of cationic lipids for siRNA delivery Nat. Biotechnol. 28 2010 172 176
40. E.I. Park, Y. Mi, C. Unverzagt, H.-J. Gabius, and J.U. Baenziger The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acidα2,6GalNAc Proc. Natl. Acad. Sci. U. S. A. 102 2005 17125 17129
41. O. Khorev, D. Stokmaier, O. Schwardt, B. Cutting, and B. Ernst Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor Bioorg. Med. Chem. 16 2008 5216 5231
42. J.K. Nair, J.L.S. Willoughby, A. Chan, K. Charisse, M.R. Alam, Q. Wang, M. Hoekstra, P. Kandasamy, A.V. Kel'in, S. Milstein, N. Taneja, J. O'Shea, S. Shaikh, L. Zhang, R.J. van der Sluis, M.E. Jung, A. Akinc, R. Hutabarat, S. Kuchimanchi, K. Fitzgerald, T. Zimmermann, T.J.C. van Berkel, M.A. Maier, K.G. Rajeev, and M. Manoharan Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing J. Am. Chem. Soc. 136 2014 16958 16961
43. D.B. Rozema, D.L. Lewis, D.H. Wakefield, S.C. Wong, J.J. Klein, P.L. Roesch, S.L. Bertin, T.W. Reppen, Q. Chu, A.V. Blokhin, J.E. Hagstrom, and J.A. Wolff Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes Proc. Natl. Acad. Sci. U. S. A. 104 2007 12982 12987
44. S.C. Wong, J.J. Klein, H.L. Hamilton, Q. Chu, C.L. Frey, V.S. Trubetskoy, J. Hegge, D. Wakefield, D.B. Rozema, and D.L. Lewis Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo Nucleic Acid Ther. 22 2012 380 390
45. A.L. Jackson, and A.A. Levin Developing microRNA therapeutics: approaching the unique complexities Nucleic Acid Ther. 22 2012 213 225
46. H.L.A. Janssen, H.W. Reesink, E.J. Lawitz, S. Zeuzem, M. Rodriguez-Torres, K. Patel, A.J. van der Meer, A.K. Patick, A. Chen, Y. Zhou, R. Persson, B.D. King, S. Kauppinen, A.A. Levin, and M.R. Hodges Treatment of HCV infection by targeting microRNA N. Engl. J. Med. 368 2013 1685 1694
47. L.F.R. Gebert, M.A.E. Rebhan, S.E.M. Crivelli, R. Denzler, M. Stoffel, and J. Hall Miravirsen (SPC3649) can inhibit the biogenesis of miR-122 Nucleic Acids Res. 42 2014 609 621
48. A. Sehgal, A. Vaishnaw, and K. Fitzgerald Liver as a target for oligonucleotide therapeutics J. Hepatol. 59 2013 1354 1359
49. S.A. Barros, and J.A. Gollob Safety profile of RNAi nanomedicines Adv. Drug Deliv. Rev. 64 2012 1730 1737
50. D. Kornbrust, J. Cavagnaro, A. Levin, J. Foy, P. Pavco, C. Gamba-Vitalo, and A. Guimond Oligo safety working group exaggerated pharmacology subcommittee consensus document Nucleic Acid Ther. 23 2013 21 28
51. J.P. Overington, B. Al-Lazikani, and A.L. Hopkins How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996
52. S. Singh, A.S. Narang, and R.I. Mahato Subcellular fate and off-target effects of siRNA, shRNA, and miRNA Pharm. Res. 28 2011 2996 3015
53. M. Sioud Recent advances in small interfering RNA sensing by the immune system New Biotechnol. 27 2010 236 242
54. S. Shukla, C.S. Sumaria, and P.I. Pradeepkumar Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook ChemMedChem 5 2010 328 349
55. J.C. Burnett, J.J. Rossi, and K. Tiemann Current progress of siRNA/shRNA therapeutics in clinical trials Biotechnol. J. 6 2011 1130 1146
56. J. DeVincenzo, R. Lambkin-Williams, T. Wilkinson, J. Cehelsky, S. Nochur, E. Walsh, R. Meyers, J. Gollob, and A. Vaishnaw A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus Proc. Natl. Acad. Sci. U. S. A. 107 2010 8800 8805
57. M. Byrne, R. Tzekov, Y. Wang, A. Rodgers, J. Cardia, G. Ford, K. Holton, L. Pandarinathan, J. Lapierre, W. Stanney, K. Bulock, S. Shaw, L. Libertine, K. Fettes, A. Khvorova, S. Kaushal, and P. Pavco Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye J. Ocul. Pharmacol. Ther. 29 2013 855 864
58. B.A. Molitoris, P.C. Dagher, R.M. Sandoval, S.B. Campos, H. Ashush, E. Fridman, A. Brafman, A. Faerman, S.J. Atkinson, J.D. Thompson, H. Kalinski, R. Skaliter, S. Erlich, and E. Feinstein siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury J. Am. Soc. Nephrol. 20 2009 1754 1764
59. J.D. Heidel, and T. Schluep Cyclodextrin-containing polymers: versatile platforms of drug delivery materials J. Drug Deliv. 2012 2012
60. C.N. Landen, W.M. Merritt, L.S. Mangala, A.M. Sanguino, C. Bucana, C. Lu, Y.G. Lin, L.Y. Han, A.A. Kamat, R.E. Schmandt, R.L. Coleman, D.M. Gershenson, G. Lopez-Berestein, and A.K. Sood Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer Cancer Biol. Ther. 5 2006 1708 1713
61. S.A. Leachman, R.P. Hickerson, M.E. Schwartz, E.E. Bullough, S.L. Hutcherson, K.M. Boucher, C.D. Hansen, M.J. Eliason, G.S. Srivatsa, D.J. Kornbrust, F.J. Smith, W.I. McLean, L.M. Milstone, and R.L. Kaspar First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder Mol. Ther. 18 2010 442 446
62. M. Aleku, P. Schulz, O. Keil, A. Santel, U. Schaeper, B. Dieckhoff, O. Janke, J. Endruschat, B. Durieux, N. Röder, K. Löffler, C. Lange, M. Fechtner, K. Möpert, G. Fisch, S. Dames, W. Arnold, K. Jochims, K. Giese, B. Wiedenmann, A. Scholz, and J. Kaufmann Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression Cancer Res. 68 2008 9788 9798
63. V. Fehring, U. Schaeper, K. Ahrens, A. Santel, O. Keil, M. Eisermann, K. Giese, and J. Kaufmann Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC Mol. Ther. 22 2014 811 820
64. D.U. Lee, W. Huang, K.D. Rittenhouse, and B. Jessen Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease J. Ocul. Pharmacol. Ther. 28 2012 222 230
65. E.C.R. Solano, D.J. Kornbrust, A. Beaudry, J.W.D. Foy, D.J. Schneider, and J.D. Thompson Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection Nucleic Acid Ther. 24 2014 258 266
66. E. Zorde Khvalevsky, R. Gabai, I.H. Rachmut, E. Horwitz, Z. Brunschwig, A. Orbach, A. Shemi, T. Golan, A.J. Domb, E. Yavin, H. Giladi, L. Rivkin, A. Simerzin, R. Eliakim, A. Khalaileh, A. Hubert, M. Lahav, Y. Kopelman, E. Goldin, A. Dancour, Y. Hants, S. Arbel-Alon, R. Abramovitch, A. Shemi, and E. Galun Mutant KRAS is a druggable target for pancreatic cancer Proc. Natl. Acad. Sci. U. S. A. 110 2013 20723 20728
67. C. Wan, T.M. Allen, and P.R. Cullis Lipid nanoparticle delivery systems for siRNA-based therapeutics Drug Deliv. Transl. Res. 4 2014 74 83
68. Y. Sato, K. Murase, J. Kato, M. Kobune, T. Sato, Y. Kawano, R. Takimoto, K. Takada, K. Miyanishi, T. Matsunaga, T. Takayama, and Y. Niitsu Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone Nat. Biotechnol. 26 2008 431 442
69. H. Dudek, D.H. Wong, R. Arvan, A. Shah, K. Wortham, B. Ying, R. Diwanji, W. Zhou, B. Holmes, H. Yang, W.A. Cyr, Y. Zhou, A. Shah, R. Farkiwala, M. Lee, Y. Li, G.R. Rettig, M.A. Collingwood, S.K. Basu, M.A. Behlke, and B.D. Brown Knockdown of [beta]-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo Mol. Ther. 22 2014 92 101
70. J. Wang, Z. Lu, M. Wientjes, and J. Au Delivery of siRNA therapeutics: barriers and carriers AAPS J. 12 2010 492 503
71. R.L. Kanasty, K.A. Whitehead, A.J. Vegas, and D.G. Anderson Action and reaction: the biological response to siRNA and its delivery vehicles Mol. Ther. 20 2012 513 524
72. M. Dominska, and D.M. Dykxhoorn Breaking down the barriers: siRNA delivery and endosome escape J. Cell Sci. 123 2010 1183 1189
73. A.K. Varkouhi, M. Scholte, G. Storm, and H.J. Haisma Endosomal escape pathways for delivery of biologicals J. Control. Release 151 2011 220 228
74. J.K. Lam, W. Liang, and H.K. Chan Pulmonary delivery of therapeutic siRNA Adv. Drug Deliv. Rev. 64 2012 1 15
75. T. Kanazawa, K. Morisaki, S. Suzuki, and Y. Takashima Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles Mol. Pharm. 11 2014 1471 1478
76. R.H.E. Chong, E. Gonzalez-Gonzalez, M.F. Lara, T.J. Speaker, C.H. Contag, R.L. Kaspar, S.A. Coulman, R. Hargest, and J.C. Birchall Gene silencing following siRNA delivery to skin via coated steel microneedles: in vitro and in vivo proof-of-concept J. Control. Release 166 2013 211 219
77. R.P. Hickerson, W.C. Wey, D.L. Rimm, T. Speaker, S. Suh, M.A. Flores, E. Gonzalez-Gonzalez, D. Leake, C.H. Contag, and R.L. Kaspar Gene silencing in skin after deposition of self-delivery siRNA with a motorized microneedle array device Mol. Ther. Nucleic Acids 2 2013 e129
78. O.M. Merkel, I. Rubinstein, and T. Kissel siRNA delivery to the lung: what's new? Adv. Drug Deliv. Rev. 75 2014 112 128
79. B. Haraldsson, J. Nyström, and W.M. Deen Properties of the glomerular barrier and mechanisms of proteinuria Physiol. Rev. 88 2008 451 487
80. P.J. White, F. Anastasopoulos, C.W. Pouton, and B.J. Boyd Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides Expert Rev. Mol. Med. 11 2009 e10
81. Y. Takakura, R.I. Mahato, and M. Hashida Extravasation of macromolecules Adv. Drug Deliv. Rev. 34 1998 93 108
82. S. Lau, B. Graham, N. Cao, B.J. Boyd, C.W. Pouton, and P.J. White Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation Mol. Pharm. 9 2011 71 80
83. U. Prabhakar, H. Maeda, R.K. Jain, E.M. Sevick-Muraca, W. Zamboni, O.C. Farokhzad, S.T. Barry, A. Gabizon, P. Grodzinski, and D.C. Blakey Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology Cancer Res. 73 2013 2412 2417
84. C. Wong, T. Stylianopoulos, J. Cui, J. Martin, V.P. Chauhan, W. Jiang, Z. Popović, R.K. Jain, M.G. Bawendi, and D. Fukumura Multistage nanoparticle delivery system for deep penetration into tumor tissue Proc. Natl. Acad. Sci. U. S. A. 108 2011 2426 2431
85. E.A. Sykes, J. Chen, G. Zheng, and W.C.W. Chan Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency ACS Nano 8 2014 5696 5706
86. Y.H. Bae, and K. Park Targeted drug delivery to tumors: myths, reality and possibility J. Control. Release 153 2011 198 205
87. S. Hwang, and K. Kim Nano-enabled delivery systems across the blood-brain barrier Arch. Pharm. Res. 37 2014 24 30
88. J. Nguyen, and F.C. Szoka Nucleic acid delivery: the missing pieces of the puzzle? Acc. Chem. Res. 45 2012 1153 1162
89. R.L. Juliano, K. Carver, C. Cao, and X. Ming Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides J. Drug Target. 21 2013 27 43
90. G.J. Doherty, and H.T. McMahon Mechanisms of endocytosis Annu. Rev. Biochem. 78 2009 857 902
91. J. Huotari, and A. Helenius Endosome maturation EMBO J. 30 2011 3481 3500
92. K. Sandvig, S. Pust, T. Skotland, and B. van Deurs Clathrin-independent endocytosis: mechanisms and function Curr. Opin. Cell Biol. 23 2011 413 420
93. R.L. Juliano, X. Ming, and O. Nakagawa Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides Bioconjug. Chem. 23 2012 147 157
94. S. Kumari, S. Mg, and S. Mayor Endocytosis unplugged: multiple ways to enter the cell Cell Res. 20 2010 256 275
95. C.G. Angers, and A.J. Merz New links between vesicle coats and Rab-mediated vesicle targeting Semin. Cell Dev. Biol. 22 2011 18 26
96. K.J. Verhey, and J.W. Hammond Traffic control: regulation of kinesin motors Nat. Rev. Mol. Cell Biol. 10 2009 765 777
97. A. Akinc, M. Thomas, A.M. Klibanov, and R. Langer Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis J. Gene Med. 7 2005 657 663
98. I.A. Khalil, K. Kogure, H. Akita, and H. Harashima Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery Pharmacol. Rev. 58 2006 32 45
99. K. Kusumoto, H. Akita, T. Ishitsuka, Y. Matsumoto, T. Nomoto, R. Furukawa, A. El-Sayed, H. Hatakeyama, K. Kajimoto, Y. Yamada, K. Kataoka, and H. Harashima Lipid envelope-type nanoparticle incorporating a multifunctional peptide for systemic siRNA delivery to the pulmonary endothelium ACS Nano 7 2013 7534 7541
100. M. Ogris Nucleic acid therapeutics: concepts for targeted delivery to solid tumors Ther. Deliv. 1 2010 91 107
101. D.T. Wiley, P. Webster, A. Gale, and M.E. Davis Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor Proc. Natl. Acad. Sci. U. S. A. 110 2013 8662 8667
102. C. Dufès, M. Al Robaian, and S. Somani Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells Ther. Deliv. 4 2013 629 640
103. N. Bien-Ly, Y.J. Yu, D. Bumbaca, J. Elstrott, C.A. Boswell, Y. Zhang, W. Luk, Y. Lu, M.S. Dennis, R.M. Weimer, I. Chung, and R.J. Watts Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants J. Exp. Med. 211 2014 233 244
104. R.J. Boado Blood-brain barrier transport of non-viral gene and RNAi therapeutics Pharm. Res. 24 2007 1772 1787
105. H. Kuwahara, K. Nishina, K. Yoshida, T. Nishina, M. Yamamoto, Y. Saito, W. Piao, M. Yoshida, H. Mizusawa, and T. Yokota Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein Mol. Ther. 19 2011 2213 2221
106. Y.J. Yu, Y. Zhang, M. Kenrick, K. Hoyte, W. Luk, Y. Lu, J. Atwal, J.M. Elliott, S. Prabhu, R.J. Watts, and M.S. Dennis Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci. Transl. Med. 3 2011 (84ra44)
107. S. Paris-Robidas, V. Emond, C. Tremblay, D. Soulet, and F. Calon In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor Mol. Pharmacol. 80 2011 32 39
108. G. Manich, I. Cabezón, J. del Valle, J. Duran-Vilaregut, A. Camins, M. Pallàs, C. Pelegrí, and J. Vilaplana Study of the transcytosis of an anti-transferrin receptor antibody with a Fab′ cargo across the blood-brain barrier in mice Eur. J. Pharm. Sci. 49 2013 556 564
109. J.A. Couch, Y.J. Yu, Y. Zhang, J.M. Tarrant, R.N. Fuji, W.J. Meilandt, H. Solanoy, R.K. Tong, K. Hoyte, W. Luk, Y. Lu, K. Gadkar, S. Prabhu, B.A. Ordonia, Q. Nguyen, Y. Lin, Z. Lin, M. Balazs, K. Scearce-Levie, J.A. Ernst, M.S. Dennis, and R.J. Watts Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier Sci. Transl. Med. 5 2013 (183ra157)
110. I. van Rooy, E. Mastrobattista, G. Storm, W.E. Hennink, and R.M. Schiffelers Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain J. Control. Release 150 2011 30 36
111. Y. Zhang, Y.-f. Zhang, J. Bryant, A. Charles, R.J. Boado, and W.M. Pardridge Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer Clin. Cancer Res. 10 2004 3667 3677
112. P. Youn, Y. Chen, and D.Y. Furgeson A myristoylated cell-penetrating peptide bearing a transferrin receptor-targeting sequence for neuro-targeted siRNA delivery Mol. Pharm. 11 2014 486 495
113. P. Kumar, H. Wu, J.L. McBride, K.-E. Jung, M. Hee Kim, B.L. Davidson, S. Kyung Lee, P. Shankar, and N. Manjunath Transvascular delivery of small interfering RNA to the central nervous system Nature 448 2007 39 43
114. L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, and M.J. Wood Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat. Biotechnol. 29 2011 341 345
115. W. Hwang do, S. Son, J. Jang, H. Youn, S. Lee, D. Lee, Y.S. Lee, J.M. Jeong, W.J. Kim, and D.S. Lee A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA Biomaterials 32 2011 4968 4975
116. Y. Tao, J. Han, and H. Dou Brain-targeting gene delivery using a rabies virus glycoprotein peptide modulated hollow liposome: bio-behavioral study J. Mater. Chem. 22 2012 11808 11815
117. Y. Liu, R. Huang, L. Han, W. Ke, K. Shao, L. Ye, J. Lou, and C. Jiang Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles Biomaterials 30 2009 4195 4202
118. M.J. Schnell, J.P. McGettigan, C. Wirblich, and A. Papaneri The cell biology of rabies virus: using stealth to reach the brain Nat. Rev. Microbiol. 8 2010 51 61
119. M. Lafon Rabies virus receptors J. Neurovirol. 11 2005 82 87
120. H. Valadi, K. Ekström, A. Bossios, M. Sjöstrand, J.J. Lee, and J.O. Lötvall Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Nat. Cell Biol. 9 2007 654 659
121. S. El Andaloussi, S. Lakhal, I. Mäger, and M.J.A. Wood Exosomes for targeted siRNA delivery across biological barriers Adv. Drug Deliv. Rev. 65 2013 391 397
122. X. Zhuang, X. Xiang, W. Grizzle, D. Sun, S. Zhang, R.C. Axtell, S. Ju, J. Mu, L. Zhang, L. Steinman, D. Miller, and H.-G. Zhang Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain Mol. Ther. 19 2011 1769 1779
123. S.-i. Ohno, M. Takanashi, K. Sudo, S. Ueda, A. Ishikawa, N. Matsuyama, K. Fujita, T. Mizutani, T. Ohgi, T. Ochiya, N. Gotoh, and M. Kuroda Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells Mol. Ther. 21 2013 185 191
124. Y. Takada, X. Ye, and S. Simon The integrins Genome Biol. 8 2007 215
125. C.L. Abram, and C.A. Lowell The ins and outs of leukocyte integrin signaling Annu. Rev. Immunol. 27 2009 339 362
126. D. Peer, P. Zhu, C.V. Carman, J. Lieberman, and M. Shimaoka Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1 Proc. Natl. Acad. Sci. U. S. A. 104 2007 4095 4100
127. D. Peer, E.J. Park, Y. Morishita, C.V. Carman, and M. Shimaoka Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target Science 319 2008 627 630
128. Y. Sakurai, H. Hatakeyama, Y. Sato, M. Hyodo, H. Akita, N. Ohga, K. Hida, and H. Harashima RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system J. Control. Release 173 2014 110 118
129. R. Shukla, T.P. Thomas, J. Peters, A. Kotlyar, A. Myc, and J.J.R. Baker Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates Chem. Commun. 2005 5739 5741
130. C.L. Waite, and C.M. Roth PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma Bioconjug. Chem. 20 2009 1908 1916
131. M.R. Alam, X. Ming, M. Fisher, J.G. Lackey, K.G. Rajeev, M. Manoharan, and R.L. Juliano Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA Bioconjug. Chem. 22 2011 1673 1681
132. W.B. Tan, S. Jiang, and Y. Zhang Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference Biomaterials 28 2007 1565 1571
133. A.V. Nascimento, A. Singh, H. Bousbaa, D. Ferreira, B. Sarmento, and M.M. Amiji Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model Mol. Pharm. 11 2014 3515 3527
134. M. Simon, N. Stefan, A. Plückthun, and U. Zangemeister-Wittke Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy Expert Opin. Drug Deliv. 10 2013 451 468
135. C. Dohmen, T. Frohlich, U. Lachelt, I. Rohl, H.-P. Vornlocher, P. Hadwiger, and E. Wagner Defined folate-PEG-siRNA conjugates for receptor-specific gene silencing Mol. Ther. Nucleic Acids 1 2012 e7
136. H. Lee, A.K.R. Lytton-Jean, Y. Chen, K.T. Love, A.I. Park, E.D. Karagiannis, A. Sehgal, W. Querbes, C.S. Zurenko, M. Jayaraman, C.G. Peng, K. Charisse, A. Borodovsky, M. Manoharan, J.S. Donahoe, J. Truelove, M. Nahrendorf, R. Langer, and D.G. Anderson Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery Nat. Nanotechnol. 7 2012 389 393
137. J.S. Kim, M.H. Oh, J.Y. Park, T.G. Park, and Y.S. Nam Protein-resistant, reductively dissociable polyplexes for in vivo systemic delivery and tumor-targeting of siRNA Biomaterials 34 2013 2370 2379
138. J.M. Li, Y.Y. Wang, W. Zhang, H. Su, L.N. Ji, and Z.W. Mao Low-weight polyethylenimine cross-linked 2-hydroxypopyl-beta-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA Int. J. Nanomedicine 8 2013 2101 2117
139. J. Wang, B. Dou, and Y. Bao Efficient targeted pDNA/siRNA delivery with folate-low-molecular-weight polyethyleneimine-modified pullulan as non-viral carrier Mater. Sci. Eng. C Mater. Biol. Appl. 34 2014 98 109
140. T. Ahrens, V. Assmann, C. Fieber, C.C. Termeer, P. Herrlich, M. Hofmann, and J.C. Simon CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation J. Investig. Dermatol. 116 2001 93 101
141. H.Y. Yoon, H.R. Kim, G. Saravanakumar, R. Heo, S.Y. Chae, W. Um, K. Kim, I.C. Kwon, J.Y. Lee, D.S. Lee, J.C. Park, and J.H. Park Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting J. Control. Release 172 2013 653 661
142. Y. Nishimura, H. Mieda, J. Ishii, C. Ogino, T. Fujiwara, and A. Kondo Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes J. Nanobiotechnol. 11 2013 19
143. O. Nakagawa, X. Ming, L. Huang, and R.L. Juliano Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands J. Am. Chem. Soc. 132 2010 8848 8849
144. S.-D. Li, Y.-C. Chen, M.J. Hackett, and L. Huang Tumor-targeted delivery of siRNA by self-assembled nanoparticles Mol. Ther. 16 2007 163 169
145. J. Willibald, J. Harder, K. Sparrer, K.-K. Conzelmann, and T. Carell Click-modified anandamide siRNA enables delivery and gene silencing in neuronal and immune cells J. Am. Chem. Soc. 134 2012 12330 12333
146. O. Nakagawa, X. Ming, K. Carver, and R. Juliano Conjugation with receptor-targeted histidine-rich peptides enhances the pharmacological effectiveness of antisense oligonucleotides Bioconjug. Chem. 25 2014 165 170
147. E. Song, P. Zhu, S.K. Lee, D. Chowdhury, S. Kussman, D.M. Dykxhoorn, Y. Feng, D. Palliser, D.B. Weiner, P. Shankar, W.A. Marasco, and J. Lieberman Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Nat. Biotechnol. 23 2005 709 717
148. Y.D. Yao, T.M. Sun, S.Y. Huang, S. Dou, L. Lin, J.N. Chen, J.B. Ruan, C.Q. Mao, F.Y. Yu, M.S. Zeng, J.Y. Zang, Q. Liu, F.X. Su, P. Zhang, J. Lieberman, J. Wang, and E. Song Targeted delivery of PLK1-siRNA by ScFv suppresses Her2 + breast cancer growth and metastasis Sci. Transl. Med. 4 2012 (130ra148)
149. T. Zhang, C.-Y. Wang, W. Zhang, Y.-W. Gao, S.-T. Yang, T.-C. Wang, R.-Z. Zhang, C. Qin, and X.-Z. Xia Generation and characterization of a fusion protein of single-chain fragment variable antibody against hemagglutinin antigen of avian influenza virus and truncated protamine Vaccine 28 2010 3949 3955
150. F.M. Uckun, S. Qazi, I. Dibirdik, and D.E. Myers Rational design of an immunoconjugate for selective knock-down of leukemia-specific E2A-PBX1 fusion gene expression in human Pre-B leukemia Integr. Biol. 5 2013 122 132
151. J. Winkler Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides Ther. Deliv. 2 2011 891 905
152. K. Ezzat, S.E. Andaloussi, E.M. Zaghloul, T. Lehto, S. Lindberg, P.M. Moreno, J.R. Viola, T. Magdy, R. Abdo, P. Guterstam, R. Sillard, S.M. Hammond, M.J. Wood, A.A. Arzumanov, M.J. Gait, C.I. Smith, M. Hallbrink, and U. Langel PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation Nucleic Acids Res. 39 2011 5284 5298
153. T. Wurch, A. Pierré, and S. Depil Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept Trends Biotechnol. 30 2012 575 582
154. J. Winkler, P. Martin-Killias, A. Pluckthun, and U. Zangemeister-Wittke EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins Mol. Cancer Ther. 8 2009 2674 2683
155. E.J. Lee, E. Lee, H.J. Kim, J.-H. Lee, K.-Y. Ahn, J.-S. Park, and J. Lee Self-assembled proteinticle nanostructures for 3-dimensional display of antibodies Nanoscale 6 2014 14919 14925
156. E.J. Lee, S.J. Lee, Y.-S. Kang, J.H. Ryu, K.C. Kwon, E. Jo, J.Y. Yhee, I.C. Kwon, K. Kim, and J. Lee Engineered proteinticles for targeted delivery of siRNA to cancer cells Adv. Funct. Mater. 2015 10.1002/adfm.201403680 (in press)
157. A. Beck, and J.M. Reichert Antibody-drug conjugates MAbs 6 2014 15 17
158. S. Panowski, S. Bhakta, H. Raab, P. Polakis, and J.R. Junutula Site-specific antibody drug conjugates for cancer therapy MAbs 6 2014 34 45
159. M. Tan, J.-M. Vernes, J. Chan, T.L. Cuellar, A. Asundi, C. Nelson, V. Yip, B. Shen, R. Vandlen, C. Siebel, and Y.G. Meng Real-time quantification of antibody-short interfering RNA conjugate in serum by antigen capture reverse transcription-polymerase chain reaction Anal. Biochem. 430 2012 171 178
160. U.H. Weidle, J. Auer, U. Brinkmann, G. Georges, and G. Tiefenthaler The emerging role of new protein scaffold-based agents for treatment of cancer Cancer Genomics Proteomics 10 2013 155 168
161. D.R. Elias, A. Poloukhtine, V. Popik, and A. Tsourkas Effect of ligand density, receptor density, and nanoparticle size on cell targeting Nanomed. Nanotechnol. 9 2013 194 201
162. M. Gebauer, and A. Skerra Anticalins: small engineered binding proteins based on the lipocalin scaffold Chapter seven K.D. Wittrup, L.V. Gregory, Methods Enzymol 2012 Academic Press 157 188
163. R. Tamaskovic, M. Simon, N. Stefan, M. Schwill, and A. Plückthun Designed ankyrin repeat proteins (DARPins): from research to therapy K.D. Wittrup, L.V. Gregory, Methods Enzymol 2012 Academic Press 101 134
164. H.M. Aliabadi, B. Landry, C. Sun, T. Tang, and H. Uludaʇ Supramolecular assemblies in functional siRNA delivery: where do we stand? Biomaterials 33 2012 2546 2569
165. J. Zhou, K.-T. Shum, J. Burnett, and J. Rossi Nanoparticle-based delivery of RNAi therapeutics: progress and challenges Pharmaceuticals 6 2013 85 107
166. H. Margus, K. Padari, and M. Pooga Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery Mol. Ther. 20 2012 525 533
167. L.C. Gomes-da-Silva, N.A. Fonseca, V. Moura, M.C. Pedroso de Lima, S. Simoes, and J.N. Moreira Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges Acc. Chem. Res. 45 2012 1163 1171
168. L. Xu, and T. Anchordoquy Drug delivery trends in clinical trials and translational medicine: Challenges and opportunities in the delivery of nucleic acid-based therapeutics J. Pharm. Sci. 100 2011 38 52
169. A.M. Jhaveri, and V.P. Torchilin Multifunctional polymeric micelles for delivery of drugs and siRNA Front. Pharmacol. 5 2014
170. K. Singha, R. Namgung, and W.J. Kim Polymers in small-interfering RNA delivery Nucleic Acid Ther. 21 2011 133 147
171. S. Höbel, and A. Aigner Polyethylenimines for siRNA and miRNA delivery in vivo Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5 2013 484 501
172. M. Breunig, U. Lungwitz, R. Liebl, and A. Goepferich Breaking up the correlation between efficacy and toxicity for nonviral gene delivery Proc. Natl. Acad. Sci. U. S. A. 104 2007 14454 14459
173. W.T. Godbey, K.K. Wu, and A.G. Mikos Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability Biomaterials 22 2001 471 480
174. J.E. Dahlman, C. Barnes, O.F. Khan, A. Thiriot, S. Jhunjunwala, T.E. Shaw, Y. Xing, H.B. Sager, G. Sahay, L. Speciner, A. Bader, R.L. Bogorad, H. Yin, T. Racie, Y. Dong, S. Jiang, D. Seedorf, A. Dave, K. Singh Sandhu, M.J. Webber, T. Novobrantseva, V.M. Ruda, K.R. Lytton-JeanAbigail, C.G. Levins, B. Kalish, D.K. Mudge, M. Perez, L. Abezgauz, P. Dutta, L. Smith, K. Charisse, M.W. Kieran, K. Fitzgerald, M. Nahrendorf, D. Danino, R.M. Tuder, U.H. von Andrian, A. Akinc, D. Panigrahy, A. Schroeder, V. Koteliansky, R. Langer, and D.G. Anderson In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight Nat. Nanotechnol. 9 2014 648 655
175. R. Sawant, and V. Torchilin Challenges in development of targeted liposomal therapeutics AAPS J. 14 2012 303 315
176. M.P. Monopoli, C. Aberg, A. Salvati, and K.A. Dawson Biomolecular coronas provide the biological identity of nanosized materials Nat. Nanotechnol. 7 2012 779 786
177. M.P. Monopoli, D. Walczyk, A. Campbell, G. Elia, I. Lynch, F. Baldelli Bombelli, and K.A. Dawson Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles J. Am. Chem. Soc. 133 2011 2525 2534
178. F. Iversen, C. Yang, F. Dagnæs-Hansen, D.H. Schaffert, J. Kjems, and S. Gao Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice Theranostics 3 2013 201 209
179. Z. Gaziova, V. Baumann, A.-M. Winkler, and J. Winkler Chemically defined polyethylene glycol siRNA conjugates with enhanced gene silencing effect Bioorg. Med. Chem. 22 2014 2320 2326
180. N. Shokrzadeh, A.-M. Winkler, M. Dirin, and J. Winkler Oligonucleotides conjugated with short chemically defined polyethylene glycol chains are efficient antisense agents Bioorg. Med. Chem. Lett. 24 2014 5758 5761
181. A. Akinc, A. Zumbuehl, M. Goldberg, E.S. Leshchiner, V. Busini, N. Hossain, S.A. Bacallado, D.N. Nguyen, J. Fuller, R. Alvarez, A. Borodovsky, T. Borland, R. Constien, A. de Fougerolles, J.R. Dorkin, K. Narayanannair Jayaprakash, M. Jayaraman, M. John, V. Koteliansky, M. Manoharan, L. Nechev, J. Qin, T. Racie, D. Raitcheva, K.G. Rajeev, D.W.Y. Sah, J. Soutschek, I. Toudjarska, H.-P. Vornlocher, T.S. Zimmermann, R. Langer, and D.G. Anderson A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Nat. Biotechnol. 26 2008 561 569
182. J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavine, R.K. Pandey, T. Racie, K.G. Rajeev, I. Rohl, I. Toudjarska, G. Wang, S. Wuschko, D. Bumcrot, V. Koteliansky, S. Limmer, M. Manoharan, and H.P. Vornlocher Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs Nature 432 2004 173 178
183. K. Nishina, T. Unno, Y. Uno, T. Kubodera, T. Kanouchi, H. Mizusawa, and T. Yokota Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol Mol. Ther. 16 2008 734 740
184. R.L. Juliano, X. Ming, and O. Nakagawa The chemistry and biology of oligonucleotide conjugates Acc. Chem. Res. 45 2012 1067 1076
185. H. Lonnberg Solid-phase synthesis of oligonucleotide conjugates useful for delivery and targeting of potential nucleic acid therapeutics Bioconjug. Chem. 20 2009 1065 1094
186. Time to deliver Nat. Biotechnol. 32 2014 (961-961)